Personalised Adaptive Medicine

Projektinformationen

PERAMEDIC

ID Finanzhilfevereinbarung: 101130241

DOI

10.3030/101130241

EK-Unterschriftsdatum 26 Oktober 2023

Startdatum 1 Februar 2024

Enddatum 31 Januar 2027

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

€ 1 726 876,90

EU-Beitrag

€ 1 726 876,90

Koordiniert durch

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany

Periodic Reporting for period 1 - PERAMEDIC (Personalised Adaptive Medicine)

Berichtszeitraum: 2024-02-01 bis 2025-01-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

In modern healthcare, the ‘one-size-fits-all’ approach to medication often fails to address the unique needs of individual patients. Genetic differences, metabolic variations, and lifestyle factors influence drug efficacy, leading to suboptimal treatment outcomes, side effects, and poor adherence. This challenge is particularly relevant for individuals managing chronic conditions, such as diabetes or cardiovascular diseases, where precise dosing and timed drug release are crucial. The PERAMEDIC project aims to overcome these limitations by developing a custom medicine printing platform capable of manufacturing personalised polypills with tailored drug release profiles. By integrating pharmaceutical advancements, adaptive microprinting, and precision dosing, PERAMEDIC seeks to transform drug formulation and administration.
Personalised medicine remains difficult to implement due to challenges in drug manufacturing, regulatory approval, and cost-effectiveness. PERAMEDIC addresses these issues by leveraging advanced 3D printing technology to produce patient-specific medication in a scalable and adaptable manner. This approach ensures that multiple active pharmaceutical ingredients can be incorporated into a single pill, allowing for controlled release tailored to individual medical needs. The project aims to simplify complex medication regimens, improving adherence while reducing the risk of adverse drug interactions.
PERAMEDIC will improve therapeutic efficacy and reduce side effects by delivering optimal dosing and controlled drug release. By enabling small-batch, on-demand manufacturing, it will introduce a new paradigm in pharmaceutical production, making personalised medicine a viable reality. The project’s success will also contribute to healthcare system efficiency by reducing hospital visits and medication-related complications.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The PERAMEDIC project has advanced the development of a personalised medicine printing platform by formulating and testing novel pharmaceutical filaments with distinct dissolution profiles, enabling exceptional control of drug release. In vitro testing confirmed their suitability for 3D printing applications, and further investigations are underway to refine drug release kinetics.
A major achievement is the development of a robust adaptive microprinting process, enabling the creation of polypills with multiple compartments. This technique allows precise deposition of pharmaceutical ingredients within controlled-release enclosures, ensuring accurate dosing tailored to patient-specific needs. Studies on pill geometry, microstructure design, and erosion mechanisms are being conducted to achieve drug release profile models. Custom software will be created to accurately predict release patterns with real-world patient data, enabling the prescription of personalised dosage forms.
The precision dosing system and novel dispensing mechanisms are being refined for particle formulation techniques and powder flow properties that will match the challenging requirements of this technology.
While testing of the key system modules will continue, their hardware and operational integration will be the lead activity over the next period. Early-stage regulatory discussions with relevant authorities on compliance requirements guide the development, paving the way for future validation.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The PERAMEDIC project has advanced beyond the current state of the art by demonstrating the feasibility of personalised polypill manufacturing through 3D printing and precision powder dosing. Unlike conventional pharmaceutical production, which relies on mass manufacturing of fixed-dose medications, PERAMEDIC introduces a modular, patient-specific approach that enables precise control over drug composition, release kinetics, and dosing accuracy. The development of customised filaments with tailored dissolution profiles represents a major breakthrough, allowing for individualised drug release patterns that align with specific therapeutic needs. Another key innovation is the adaptive microprinting technology, which enables the fabrication of complex polypill structures with multiple compartments, each programmed for individually controlled drug release. Additionally, the project’s precision dosing system, based on advanced powder deposition techniques, ensures unparalleled accuracy in the placement of active ingredients in their native and highly stable powder form, addressing a critical limitation in existing personalised medicine approaches.

Logo